Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
‘Slender Man’ attacker back in custody. What we know about Morgan Geyser's disappearance and what happens next. - 2SpaceX launches Starlink satellites from California on 160th Falcon 9 flight of the year (video)
- 3Building Tough Connections: Individual Bits of knowledge on Association
- 4Some Americans say they'll go without health insurance as ACA rates spike
- 5Kona SUV: Exploring the Future with Hyundai's Visionary Hybrid
- Baikonur launch pad damaged after Russian Soyuz launch to International Space Station
- Spain's Easter processions draw more tourists amid Iran war
- Death toll from floods in Afghanistan rises to 61
- Bayer reports positive results for blood thinner after 2023 setback
- Vote in favor of your Favored sort of footwear
- Astronauts' brains change shape and position after time in space, study finds
- Common ADHD medication prescribed in childhood may protect against risk of psychosis
- Lula’s former human rights minister formally accused of sexual misconduct
- The Best Internet Mastering Stages for Expertise Improvement
